Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
- Tablet Terminals Effective for Changing Doctors’ Prescribing Behavior: M3
September 12, 2011
- MTPC Applies for DPP-4 Inhibitor Teneligliptin
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- Ethical Drugs Sales Rise 5.3% in 2nd Quarter: IMS Japan
September 12, 2011
- Market for Anti-RA Drugs to Exceed ¥300 Bil. in 2019: Fuji-Keizai
September 12, 2011
- Mizuho Forecasts Higher Sales, Lower Profits for 9 Major Domestic Drug Makers in FY2011
September 12, 2011
- Nomura Securities Raises Target Share Prices for 3 Drug Wholesalers
September 12, 2011
- Kissei Obtains Japan Rights for Anthracycline Extravasation Agent
September 12, 2011
- Astellas Licenses Fully-Human Antibody against Infectious Diseases from Evec
September 12, 2011
- Drug-only Warehouses at Haneda Airportto Start Full-scale Operations this Fall
September 12, 2011
- Former Employee of Regional Wholesaler Sanki Charged with Illegal Drug Sales
September 12, 2011
- More ADCs and Other Anticancer Drugs from Domestic Drug Makers Enter Late Stage Development
September 12, 2011
- Daiichi Sankyo to Transfer Part of R&D Function to Subsidiary
September 12, 2011
- PIII Trial for Type 2 Diabetes Treatment SYR-472 Started in Japan: Takeda
September 9, 2011
- Afinitor Approved for Pancreatic NET in Europe: Novartis
September 9, 2011
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…